In Dec 2017, Neon signed clinical research collaborative with Merck (known as MSD) to evaluate Neon Therapeutics proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Mercks anti-PD-1 therapy, KEYTRUDAë (pembrolizumab), along with chemotherapy. Additional details were not disclosed.

In July 2017, CRISPR Therapeutics (NASDAQ:CRSP) and Neon signed a research collaboration to explore the combination of each companys proprietary technologies to develop novel T cell therapies.

In July 2017, Neon signed clinical research collaborative with Apexigen, Inc., to evaluate Neon Therapeutics proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Apexigens CD40 agonist antibody, APX005M, for the treatment of patients with metastatic melanoma.

Neon Therapeutics signs non-exclusive research collaboration with Vedantra Pharmaceuticals to Develop Novel Cancer Immunotherapies combining Vedantras cutting-edge, lymph node targeting amphiphile technology with Neons innovative capabilities in neoantigen vaccine research.

In Feb 2016, Neon signed collaborative research agreement with Netherlands Cancer Institutes (NKI) Antoni van Leeuwenhoek Hospital and Amsterdam Biotherapeutics Unit to combine complementary capabilities to develop personalized T cell therapies.

In Feb 2016, Neon signed collaborative research agreement with Sanquin Blood Supply Foundation for its technology to be utilized across Neon Therapeutics pipeline. The technology utilizes ultraviolet light-based exchange for fast and simple generation of large series of peptide-MHC complexes for in vitro and ex vivo detection and characterization of antigen-specific T cells.

In Dec 2015, Neon Therapeutics, singed a clinical trial collaboration with Bristol-Myers Squibb to evaluate the combination of Neon Therapeutics proprietary personalized neoantigen vaccine, NEO-PV-01, and Opdivoë (nivolumab), a PD-1 immune checkpoint inhibitor. Additional details of the collaboration were not disclosed.